Damora Therapeutics, Inc. (DMRA): Operating Income
-$210.87M
Year ended 2025-12-31
-$270.66M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$210.87M | n/m | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | -$22.26M | n/m | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | -$39.91M | n/m | 2025-03-19, From 2023-01-01 |
| 2022-12-31 | -$61.21M | n/m | 2024-03-08, From 2022-01-01 |
| 2021-12-31 | -$52.23M | n/m | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | -$33.64M | n/c | 2022-02-17, From 2020-01-01 |
| 2019-12-31 | $38.97M | n/a | 2021-03-29, From 2019-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | 2025-12-31 | -$210.87M | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $24.74M | +23.1% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$159.99M | n/m |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | -$12.12M | n/m |
| Macrogenics Inc (MGNX) | 2025-12-31 | -$72.84M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$2.54M | n/m |
| Perspective Therapeutics, Inc. (CATX) | 2025-12-31 | -$113.56M | n/m |
| Savara Inc (SVRA) | 2025-12-31 | -$123.55M | n/m |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | -$76.26M | n/m |
Compare DMRA, NATR, PHAT, ASMB side by side · Screen every company in Pharmaceutical Preparations ↗